Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). New England Journal of Medicine.
Summary
The SELECT trial, which asked whether semaglutide reduces cardiovascular risk in people who are overweight or obese but do not have diabetes, a question earlier trials had only answered for people with diabetes. More than 17,000 patients with existing cardiovascular disease were randomised to weekly semaglutide or placebo, with the primary endpoint a combination of death from cardiovascular causes, non-fatal heart attack and non-fatal stroke. The largest trial of any substance covered on this site, and the source of the cardiovascular claim on the semaglutide page.